Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 8/20 | 0.38 |
| ▸ | CTSG | P08311 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SLC37A4 | O43826 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7478652 | 0.75 | MEN1 (0.39) | MEN1KMT2AMAOAMAOBEPHX2 | |
| SCHEMBL7462411 | 0.72 | MAOA (0.54) | MEN1KMT2AMAOAMAOBEPHX2 | |
| SCHEMBL7462323 | 0.71 | MEN1 (0.68) | MEN1KMT2AMAOAMAOBEPHX2 | |
| SCHEMBL16656216 | 0.71 | MAOA (0.58) | MEN1KMT2AMAOAMAOBEPHX2 | |
| SCHEMBL7482879 | 0.70 | MEN1 (0.43) | MEN1KMT2AMAOAMAOBEPHX2 | |
| SCHEMBL31441204 | 0.68 | MAOA (0.70) | MEN1KMT2AMAOAMAOBEPHX2 | |
| SCHEMBL30420953 | 0.66 | MAPT (0.75) | MEN1KMT2AMAOAMAOBTTR | |
| SCHEMBL2076402 | 0.66 | MAPT (0.75) | MEN1KMT2AMAOAMAOBTTR | |
| SCHEMBL8136100 | 0.65 | CYP24A1 (0.32) | — | |
| SCHEMBL7792651 | 0.65 | MAOA (0.62) | MEN1KMT2AMAOAMAOBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1023293-A4 | ARYLOXYMETHYL CARBAPENEM ANTIBACTERIALS | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
| EP-1032384-A4 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6284753-B2 | GRAMPOSITVE BACTERIA | MERCK & CO., INC. | 2001-09-04 | — | — | US | disclosed |
| US-6277843-B1 | USEFUL AGAINST GRAMPOSITIVE BACTERIA, I.E., METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS, WITH REDUCED SIDE EFFECTS | MERCK & CO., INC. | 2001-08-21 | — | — | US | disclosed |
| US-20010011086-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. | 2001-08-02 | — | — | US | disclosed |
| US-6207823-B1 | ANTIBIOTIC; ANTIBIOTIC RESISTANT INFECTIONS | MERCK & CO., INC. | 2001-03-27 | — | — | US | disclosed |
| EP-1032384-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2000-09-06 | — | — | EP | disclosed |
| EP-1023293-A1 | ARYLOXYMETHYL CARBAPENEM ANTIBACTERIALS | Merck & Co., Inc. (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999020270-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999014217-A1 | ARYLOXYMETHYL CARBAPENEM ANTIBACTERIALS | MERCK & CO., INC. (US) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011086-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | TOP1, NRDC, PAICS | MEN1 2142/4885KMT2A 2756/4885MAOA 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.